Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

14 trials with published results (27%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

5.9%

3 terminated out of 51 trials

Success Rate

92.1%

+5.6% vs benchmark

Late-Stage Pipeline

31%

16 trials in Phase 3/4

Results Transparency

40%

14 of 35 completed with results

Key Signals

14 with results92% success

Data Visualizations

Phase Distribution

48Total
Not Applicable (14)
Early P 1 (1)
P 1 (8)
P 2 (9)
P 3 (14)
P 4 (2)

Trial Status

Completed35
Recruiting6
Terminated3
Not Yet Recruiting2
Withdrawn2
Unknown2

Trial Success Rate

92.1%

Benchmark: 86.5%

Based on 35 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT07568236Phase 2Not Yet RecruitingPrimary

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

NCT06628388Not ApplicableActive Not RecruitingPrimary

Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong

NCT07064850CompletedPrimary

Vasomotor Symptoms in Post-Hysterectomy Women With Ovarian Conservation

NCT06957691Phase 2Recruiting

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT07408115Not ApplicableCompleted

Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women

NCT07335224Not ApplicableRecruiting

Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture

NCT07229404Phase 1CompletedPrimary

A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants

NCT04090957Phase 3CompletedPrimary

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

NCT02803268Phase 1CompletedPrimary

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms

NCT07112651Not ApplicableRecruitingPrimary

Efficacy of CL25216 on Vasomotor Symptoms in Women During Perimenopause

NCT07238478Not ApplicableRecruiting

JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women

NCT07042516Phase 2RecruitingPrimary

Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).

NCT02907983Phase 2Withdrawn

Stellate Ganglion Blockade in Post-Menopausal Women

NCT06204250Phase 1CompletedPrimary

A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers

NCT04209543Phase 3CompletedPrimary

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

NCT05367973Phase 1Completed

Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women

NCT05033886Phase 3CompletedPrimary

A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

NCT05083884Completed

A Survey About Hot Flashes in Women Going Through the Menopause

NCT05418426Phase 1Completed

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

NCT05813067Not ApplicableCompletedPrimary

Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women

Scroll to load more

Research Network

Activity Timeline